TABLE 1.
Focus on upper gastrointestinal bleeding
| Lockdown group (n = 13) (76%) | Control group (n = 24) (69%) | ||
|---|---|---|---|
| NSAID abuse, n (%) | 3 (23) | 5 (21) | 0.7700 |
| Antithrombotic treatments, n (%) | 4 (30) | 6 (25) | 0.7 |
| Onset evident bleeding (mean days) | 6.5 ± 1.6 (range 1–10) | 1.7 ± 0.6 (range 1–3) | 0.0001 |
| Hemoglobin at admission (g/dL) | 6.5 ± 2 (range 3–12) | 9.9 ± 2.5 (range 5–14) | 0.0010 |
| Need of Blood transfusion, n (%) | 13 (77) | 23 (17) | 0.0010 |
| Severity of bleeding endoscopic stigmata (Forrest classification) | Total (n = 10/13) | Total (n = 11/24) | 0.04 |
| III Clean‐based ulcer | 3 (30) | 7 (64) | |
| IIc Flat pigmented hematinic | 2 (20) | 0 | |
| IIb Adherent clot | 0 | 3 (27) | |
| IIa Non‐bleeding visible vessel | 3 (30) | 0 | |
| Ib Active oozing | 2 (20) | 1 (9) | |
| Ia Active spurter | 0 | 0 | |
| Endoscopic treatment | 5 (50) | 4 (36) | 0.52 |
| H. pylory detection, n (%) | 6 (46) | 7 (29) | 0.3 |